Has this already been posted?
I'm doing this on my phone, and I've just lost the link. I'll edit this on my PC later.
Still, an actual clinical trial for 4-AP in AMN patients.
I've just received my monthly delivery of 4-Aminopyridine-3-methanol. Excellent. I'd love to see some clinical trials of 4-ap-3-meoh in the future.
Improvement of motor function in patients with AMN
Pr. Wolfgang Köhler (Germany)
Leg stiffness and walking disabilities are leading symptoms in patients with Adrenomyeloneuropathy
(AMN). The reasons for this spasticity are spinal cord long nerve fiber and myelin damage. The nerve
fibers of the spinal cord carry the electrical impulses that transport information from and to the brain
to support the complex control system of the human body. Each microscopically thin nerve fiber is
insulated by a regular pattern of myelin sheaths along its length that allow for the efficient
conduction of electrical impulses. In AMN some of these myelin sheaths can be damaged leading to
an impairment or even disruption of neural conduction of movement information from brain to the
muscle. Nerve impulses "short circuit" in demyelinated axons, much like electricity in a wire whose
insulation is stripped. Thus, even though a demyelinated axon is alive, it is unable transmit motor or
Treatment with 4‐Aminopyridine (4‐AP) permits the axon to transmit impulses again, improve nerve
conduction thus leading to reduced spasticity and improved walking abilities in patients with multiple
sclerosis. Since in AMN similar clinical symptoms are present, we treated 18 AMN patients with 4‐AP
using a standardized study protocol. 13 out of 18 patients improved significantly regarding a timed‐
25 foot walking distance. 15 out of 18 patients reported significant reduction of spasticity and pain, 9
out of 18 improved with their bladder function. In summary treatment with 4‐AP may significantly
improve walking disabilities caused by spastic paraparesis in most patients with AMN.